

STEP THERAPY POLICY

- POLICY:** Antiepileptics – Zonisamide Step Therapy Policy
- Zonegran® (zonisamide capsules – Concordia, generic)
 - Zonisade™ (zonisamide oral suspension – Azurity)

REVIEW DATE: 11/16/2022

OVERVIEW

All of these products are indicated as adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years of age with epilepsy.^{1,2}

Zonisamide capsules are available in 25 and 100 mg strengths and should be swallowed whole.¹ Zonisade is available as a 100 mg/5 mL strawberry flavored oral suspension.²

POLICY STATEMENT

This program has been developed to encourage the use of a Step 1 Product prior to the use of a Step 2 Product. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

Automation: A patient with a of one Step 1 Product within the 130-day look-back period is excluded from Step Therapy.

Step 1: generic zonisamide capsules

Step 2: Zonisade, Zonegran (brand)

CRITERIA

1. If the patient has tried one Step 1 Product, approve a Step 2 Product.
2. If the patient cannot swallow or has difficulty swallowing solid oral dosage forms, approve Zonisade.
3. No other exceptions are recommended.

REFERENCES

1. Zonegran® capsules [prescribing information]. Wilmington, MA: Azurity; July 2022.
2. Zonisade™ oral suspension [prescribing information]. Overland Park, KS: Concordia; April 2020.

11/16/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.